Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol

Abstract

The invention refers to a pharmaceutical or nutraceutical composition comprising a core a) comprising an active ingredient and a water-insoluble polymer, a coating layer b) above the core a) comprising a salt of an alginic acid, and a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight in relation to the total weigh of the (meth)acrylate monomer mixture of (meth)acrylate monomers with an anionic group, wherein the amount of the water-insoluble polymer in the core a) is 2 to 20% by weight in relation to the weight of the corm a) and the amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a) and the amount of the anionic (meth)acrylate copolymer in the coaling layer c) is 10 to 75% by weight in relation to the weight of the care a) and to the coating layer b).

1 : A pharmaceutical or nutraceutical composition, comprising:
 a core a) comprising an active ingredient and a water-insoluble polymer;   a coating layer b) above the core a) comprising a salt of an alginic acid; and   a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight, in relation to a total weight of the (meth)acrylate monomer mixture, of (meth)acrylate monomers with an anionic group,   wherein:   an amount of the water-insoluble polymer in the core a) is 2 to 50% by weight in relation to a weight of the core a);   an amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a); and   an amount of the anionic (meth)acrylate copolymer in the coating layer c) is 10 to 75% by weight in relation to the weight of the core a) and the coating layer b); and   when the amount of polymerized monomers with anionic groups of the anionic (meth)acrylate copolymer comprised in the coating layer c) is 5 to 40% by weight in relation to a total weight of the polymerized monomers,   percentages of the amount of the salt of the alginic acid in the coating layer b) in relation to the weight of the core a) and percentages of the amount of the anionic (meth)acrylate copolymer in the coating layer c) in relation to the weight of the core a) and the coating layer b) add up to at least 50%, or   when the amount of polymerized monomers with anionic groups of the anionic (meth)acrylate copolymer comprised in the coating layer c) is more than 40 and up to 75% by weight in relation to the total weight of the polymerized monomers,   the percentages of the amount of the salt of the alginic acid in the coating layer b) in relation to the weight of the core a) and the percentages of the amount of the anionic (meth)acrylate copolymer in the coating layer c) in relation to the weight of the core a) and the coating layer b) add up to at least 60%.   
     
     
         2 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein;
 the core a) comprises an inner core a1), comprising the active ingredient and a coating layer a2), comprising the water-insoluble polymer; and the coating layer a2) is above the inner core a1) and below the coating layer b).   
     
     
         3 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein the water-insoluble polymer is selected from the group consisting of a vinyl homopolymer, a vinyl copolymer, a water-insoluble cellulose, and mixtures thereof. 
     
     
         4 - 6 . (canceled) 
     
     
         7 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein the salt of the alginic acid used for the coating layer b) has a viscosity of 30 to 720 cP in a 1% aqueous solution (weight/weight). 
     
     
         8 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein the salt of alginic acid is selected from the group consisting of sodium alginate, potassium alginate, magnesium alginate, lithium alginate, ammonium alginate, and any mixtures thereof. 
     
     
         9 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein not more than 10% of the active ingredient is released under in-vitro conditions at pH 1.2 over a period of 2 hours in a medium according to USP with and without an addition of 40% (v/v) ethanol. 
     
     
         10 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein release of the pharmaceutical or nutraceutical active ingredient is less than 60% after 4 hours and at least 60% after 6 to 10 hours under in-vitro conditions at pH 1.2 for 2 hours and subsequent buffered medium at pH 6.8 or at pH 7.4 according to USP for a remaining time. 
     
     
         11 : The pharmaceutical or nutraceutical composition according to  claim 1 , wherein the core a), the coating layer b), the coating layer c), or a combination thereof, comprise up to 80% by weight of at least one pharmaceutical or nutraceutically acceptable excipient. 
     
     
         12 : A process for producing the pharmaceutical or nutraceutical composition according to  claim 1 , the process comprising:
 forming the core a) comprising the active ingredient by direct compression, compression of dry, wet or sintered granules, by extrusion and subsequent rounding off, by wet or dry granulation, direct pelleting or by binding powders onto active ingredient-free beads or neutral cores or active ingredient-containing particles; and   applying the inner coating layer b) and the outer coating layer cl in the form of aqueous dispersions or organic solutions in spray processes or by fluidized bed spray granulation.   
     
     
         13 : A sustained release gastric resistant pharmaceutical or nutraceutical composition having resistance against the influence of alcohol, comprising the pharmaceutical or nutraceutical composition of  claim 1 .